Evidence map›Paper›PMID 41535029›Full record

ArticleInternal medicine (Tokyo, Japan)2026

The Effectiveness of Elranatamab in the Management of Refractory Multiple Myeloma with Central Nervous System Involvement.

Misaki Uemura, Atsushi Marumo, Atsushi Obata, Nana Matsumoto, Meya Li, Yuta Kaito, Yasunobu Nagata, Satoshi Wakita, Hideto Tamura, Hiroki Yamaguchi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Misaki UemuraDepartment of Hematology, Nippon Medical School, Japan.
Atsushi MarumoDepartment of Hematology, Nippon Medical School, Japan.
Atsushi ObataDepartment of Hematology, Nippon Medical School, Japan.
Nana MatsumotoDepartment of Hematology, Nippon Medical School, Japan.
Meya LiDepartment of Hematology, Nippon Medical School, Japan.
Yuta KaitoDepartment of Hematology, Nippon Medical School, Japan.
Yasunobu NagataDepartment of Hematology, Nippon Medical School, Japan.
Satoshi WakitaDepartment of Hematology, Nippon Medical School, Japan.
Hideto TamuraDivision of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Japan.
Hiroki YamaguchiDepartment of Hematology, Nippon Medical School, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma with central nervous system (CNS) involvement is rare and associated with a poor prognosis. Although the emergence of novel therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies, has made it possible to obtain long-term disease control in multiple myeloma, there is still no established standard treatment for cases with CNS involvement, and the efficacy of novel therapies remains unclear. To our knowledge, we herein report the first case of successful elranatamab treatment in Japan in a patient with refractory multiple myeloma showing impaired consciousness caused by CNS involvement.

Indexed as

Antibodies, BispecificCentral Nervous System NeoplasmsMultiple MyelomaHumansMaleTreatment OutcomeAntibodies, Bispecificbispecific antibodycentral nervous system involvementelranatamabmultiple myeloma

Identifiers

PMID41535029
PMCPMC13561560

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.